Cheryl Gault, Director at Rapport Therapeutics, Inc. (RAPP), bought 969,480 shares at $21.00 ($20.4M) on 2026-10-28, disclosed to the SEC on 2026-10-30.
Director Cheryl Gault executed a massive $20M purchase of 952,380 shares at $21.00, marking the largest insider trade in the company's history and signaling strong conviction in the stock's recovery potential. This significant accumulation comes as the stock has been hammered over the last three months, potentially presenting a contrarian entry point for sophisticated traders.
RAPP has crashed 41.11% over the last 90 days and is currently trading 54.32% below its 52-week high of $52.93, despite being only 9.51% above its 52-week low of $22.08.
Insider cluster: This is the largest insider purchase ever recorded for RAPP, indicating a high-conviction bet by company leadership.
Short interest: The stock carries a short interest of 10.07% of the float, which could lead to volatility if the stock begins to recover.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.00 | 3,772 | $79K | 0.4% |
| 2 | $21.00 | 6,395 | $134K | 0.7% |
| 3 | $21.00 | 6,933 | $146K | 0.7% |
| 4 | $21.00 | 952,380 | $20.0M | 98.2% |
| Total | $21.00 avg | 969,480 | $20.4M | 100% |
| Filing → |
| RAPP | BUY | 2026-10-22 | $100K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $249K | — | Filing → |
| RAPP | BUY | 2026-10-22 | $974K | — | Filing → |